Gene: EAF2

55840
BM040|TRAITS|U19
ELL associated factor 2
protein-coding
3q13.33
Ensembl:ENSG00000145088 MIM:607659 Vega:OTTHUMG00000159424 UniprotKB:Q96CJ1
NC_000003.12
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.765e-1 (AD)  2.075e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs9826473chr3:121837372 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
C11orf10.71
DUS4L0.69
PTPMT10.651
LSM50.651
TMEM1280.649
PEX70.644
MRPL130.642
LINC006930.64
LYPLAL10.63
PARL0.627

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.398
OR4F29-0.365
RAX2-0.346
EPPIN-0.342
BNIPL-0.332
CCNA2-0.328
REP15-0.32
SLFNL1-0.316
UPK1A-0.315
TLR9-0.313

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0235142,6-dinitrotoluene"2,6-dinitrotoluene results in decreased expression of EAF2 mRNA"20406850
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of EAF2 mRNA"23196670
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
D020106AcrylamideAcrylamide results in increased expression of EAF2 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of EAF2 mRNA21641981
D000638AmiodaroneAmiodarone results in increased expression of EAF2 mRNA19774075
D000643Ammonium ChlorideAmmonium Chloride affects the expression of EAF2 mRNA16483693
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of EAF2 mRNA22316170
D004958Estradiol[Estradiol co-treated with Progesterone] results in increased expression of EAF2 mRNA20660070
C006780bisphenol Abisphenol A affects the expression of EAF2 mRNA21786754
C006780bisphenol Abisphenol A results in decreased expression of EAF2 mRNA25181051
C018475butyraldehydebutyraldehyde results in increased expression of EAF2 mRNA26079696
D019256Cadmium ChlorideCadmium Chloride results in increased methylation of EAF2 promoter22457795
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of EAF2 mRNA16934159
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of EAF220938992
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of EAF2 gene20938992
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of EAF2 mRNA20938992
C012843cinnamic aldehydecinnamic aldehyde results in decreased expression of EAF2 mRNA19524605
D003471CuprizoneCuprizone results in decreased expression of EAF2 mRNA26577399
D016572CyclosporineCyclosporine results in increased expression of EAF2 mRNA20106945|2556210
D002945CisplatinCisplatin results in increased expression of EAF2 mRNA27594783
D002117CalcitriolCalcitriol results in increased expression of EAF2 mRNA16002434
D004121Dimethyl SulfoxideDimethyl Sulfoxide affects the expression of EAF2 mRNA24834073
D000068538DutasterideDutasteride promotes the reaction [Testosterone results in increased expression of EAF2 mRNA]20564326
D000068538DutasterideDutasteride results in decreased expression of EAF2 mRNA20564326
C118739entinostatentinostat results in increased expression of EAF2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
D018120FinasterideFinasteride promotes the reaction [Testosterone results in increased expression of EAF2 mRNA]20564326
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of EAF220938992
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of EAF2 gene20938992
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of EAF2 mRNA20938992
D005557FormaldehydeFormaldehyde results in increased expression of EAF2 mRNA23649840
C039281furanfuran results in increased expression of EAF2 mRNA25539665
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EAF2 mRNA25613284
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of EAF2 mRNA23086925
C002385linsidominelinsidomine results in increased oxidation of EAF2 protein28086193
D008148LovastatinEAF2 SNP results in decreased susceptibility to Lovastatin21483694
C042720mercuric bromidemercuric bromide results in increased expression of EAF2 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of EAF220938992
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of EAF2 gene20938992
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of EAF2 mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of EAF2 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of EAF2 mRNA23649840
D015741MetriboloneMetribolone results in increased expression of EAF2 mRNA17010675
C583365N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide"N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in decreased expression of EAF2 mRNA"29244179
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of EAF2 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of EAF2 mRNA"25554681
D009532NickelNickel results in increased expression of EAF2 mRNA24768652|2558310
C022838nickel chloridenickel chloride affects the expression of EAF2 mRNA22546817
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of EAF2 mRNA19162173
C006253pirinixic acidpirinixic acid results in increased expression of EAF2 mRNA23811191
D010936Plant ExtractsPlant Extracts results in increased expression of EAF2 mRNA21920417
D010938Plant OilsPlant Oils results in increased expression of EAF2 mRNA23370395
D011374Progesterone[Estradiol co-treated with Progesterone] results in increased expression of EAF2 mRNA20660070
D011794QuercetinQuercetin results in decreased expression of EAF2 mRNA21632981
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of EAF2 mRNA21427059
D019821SimvastatinEAF2 SNP results in decreased susceptibility to Simvastatin21483694
C016104sodium bichromatesodium bichromate results in decreased expression of EAF2 mRNA17685462
D013739TestosteroneDutasteride promotes the reaction [Testosterone results in increased expression of EAF2 mRNA]20564326
D013739TestosteroneFinasteride promotes the reaction [Testosterone results in increased expression of EAF2 mRNA]20564326
D013739TestosteroneTestosterone results in increased expression of EAF2 mRNA20564326
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of EAF2 mRNA21570461|2637764
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EAF2 mRNA25613284
C009495titanium dioxidetitanium dioxide results in increased expression of EAF2 mRNA23557971
D014212TretinoinTretinoin results in decreased expression of EAF2 mRNA23724009
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of EAF2 mRNA19042947
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of EAF2 mRNA"26179874
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of EAF2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of EAF2 mRNA23179753|2627250
D014635Valproic AcidValproic Acid affects the expression of EAF2 mRNA17963808
D014635Valproic AcidValproic Acid results in increased expression of EAF2 mRNA21427059
D014638VanadatesVanadates results in decreased expression of EAF2 mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of EAF2 gene25560391
C029297vinylidene chloridevinylidene chloride results in decreased expression of EAF2 mRNA26682919
C111237vorinostatvorinostat results in increased expression of EAF2 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IDA16114057  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IDA16114057  
GO:0005515protein binding-IPI17395368  21516116  24421387  25416956  27107012  
GO ID GO Term Qualifier Evidence PubMed
GO:0006366transcription by RNA polymerase II-TAS-  
GO:0006368transcription elongation from RNA polymerase II promoter-TAS-  
GO:0006915apoptotic process-IEA-  
GO:0030308negative regulation of cell growth-IEA-  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA16114057  
GO:0060770negative regulation of epithelial cell proliferation involved in prostate gland development-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005654nucleoplasm-TAS-  
GO:0008023transcription elongation factor complex-IDA22195968  
GO:0016607nuclear speck-IEA-  
GO:0032783ELL-EAF complex-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112382Formation of RNA Pol II elongation complex TAS
R-HSA-674695RNA Polymerase II Pre-transcription EventsTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-75955RNA Polymerase II Transcription ElongationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal